Eli Lilly and Company

At Agenus, we're driven by a singular, unwavering mission: to end the suffering of cancer patients. For over 30 years, our team of scientists, researchers, and professionals has been united by this purpose, working collaboratively across the US and Europe to discover, develop, and manufacture breakthrough immuno-oncology therapies. Our research and innovation engine has built a comprehensive pipeline of novel immunotherapies that empower the body to recognize and eliminate disease. We believe that the key to transforming cancer treatment lies in harnessing the full power of the immune system - activating it to do what it was meant to do. Our culture is defined by scientific excellence, relentless innovation, and an unwavering focus on patients. We thrive on tackling the toughest challenges in oncology, particularly in areas where current therapies fall short - cold tumors and late-stage cancers that have resisted traditional treatments. The people who thrive here are those who share our passion for making a meaningful difference, who embrace collaboration across disciplines, and who are motivated by the potential to deliver curative therapies to patients who need them most. Every day, we're pushing the boundaries of what's possible in immunotherapy, united by our vision of a future where more patients live longer, fuller lives.

In 1999, two science-based companies with shared visions came together to form AstraZeneca: Sweden's Astra AB and the UK's Zeneca Group PLC. This strategic merger combined decades of pharmaceutical expertise, creating a global powerhouse uniquely positioned to push the boundaries of scientific discovery. What began as a union of strengths has evolved into a relentless pursuit of breakthrough therapies, with the company investing billions annually in research and development to transform patient outcomes across oncology, biopharmaceuticals, respiratory, and rare diseases. Today, AstraZeneca stands at the forefront of precision medicine and next-generation therapeutics, harnessing the power of data science, AI, and innovative technologies like cell therapies. With 197 projects in the pipeline and 16 blockbuster medicines, the company operates from six strategic R&D centres spanning Cambridge, Gothenburg, Gaithersburg, Boston, Shanghai, and Beijing. Their bold aspiration to deliver 20 new medicines by 2030 reflects an unwavering commitment to following the science and putting patients first - values that have driven every decision since that pivotal merger more than two decades ago.

Alcon is the global leader in eye care, dedicated to helping people see brilliantly. With over 75 years of heritage, Alcon stands as the largest eye care device company in the world, operating in 60 countries and serving patients in more than 140 countries globally. The company's complementary businesses in Surgical and Vision Care deliver the broadest portfolio of products designed to enhance sight and improve lives. Founded in 1945 by pharmacists Robert Alexander and William Conner in Fort Worth, Texas, Alcon has built a legacy of industry firsts that continues to define the standard of care in ophthalmology. The company invests substantially in research and development, committing over $876 million annually to pioneer life-changing innovations that address unmet patient needs. From revolutionary intraocular lenses like AcrySof to advanced water gradient contact lenses such as DAILIES TOTAL1, Alcon's product pipeline encompasses more than 70 products under development. The company's integrated approach spans surgical equipment, vision correction devices, pharmaceutical treatments, and diagnostic technologies, enabling comprehensive eye care solutions across the entire patient journey. Alcon's mission-driven culture centers on the belief that when people see brilliantly, they live brilliantly.

Monte Rosa Therapeutics is a clinical-stage biotechnology company focused on developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases. The company’s work centers on degrading proteins - 'Degrading Proteins, Making Medicines' - and advancing precision approaches that target undruggable or inadequately drugged proteins with unprecedented specificity. On its website, the team is described as combining expertise in molecular glue degrader (MGD) chemistry, artificial intelligence (AI), structural biology, and proteomics. Monte Rosa’s QuEEN
9 (Quantitative and Engineered Elimination of Neosubstrates) discovery engine is described as using AI-guided chemistry alongside diverse chemical libraries, structural biology, and proteomics to identify degradable protein targets and rationally design MGDs. The company positions this platform as enabling access to a wide-ranging, differentiated target space across multiple therapeutic areas, and references advancing multiple MGD programs through its pipeline. The company is headquartered in Boston, Massachusetts, and also lists a Basel, Switzerland location on its site.

Medtronic exists to solve the world's most challenging health problems through bold innovation and advanced technology. For over 75 years, the company has pioneered groundbreaking health tech that transforms lives, treating more than 70 conditions across the human body - from heart failure to Parkinson's disease. As a global leader in healthcare technology, Medtronic leverages data, AI, and cutting-edge therapies to address complex healthcare challenges that affect millions of people worldwide. With 95,000 employees across 150 countries, the company's mission-driven approach combines medical expertise with technological innovation to restore health, extend life, and alleviate pain for patients everywhere. From its humble beginnings in a Minneapolis garage to becoming the world's largest medical technology company, Medtronic continues to push boundaries and redefine what's possible in healthcare, making a meaningful impact on global health outcomes every day through innovations that put more life into patients' years.

The purpose of Idorsia is to discover, develop, and commercialize innovative medicines to help more patients. We have more ideas, we see more opportunities, and we want to transform the horizon of therapeutic options. Headquartered in Switzerland – a biotech-hub of Europe – Idorsia is a high-potential biopharmaceutical company, specialized in the discovery, development and commercialization of innovative small molecules. Our team is dedicated to bringing innovative medicines from bench to bedside, with operations spanning multiple locations across North America, Europe, and Asia. We conduct research, clinical development, and commercial operations out of these global locations. Idorsia's corporate responsibility efforts encompass employee development and diversity, governance and ethics, as well as the organization's economic, environmental, and social performance.